BioSig Technologies, Inc.
  • Home
  • About BioSig
    • About BioSig
    • Overview
    • Partnerships
  • Our Technology
    • Our Technology
    • The PURE EP Platform
      • Overview
      • ATC
      • NFT
    • Publications
  • Join Our Team
  • News & Media
    • News & Media
    • Overview
    • Press Releases
    • BioSig in the News
    • Events
  • Investors
    • Investors
    • Overview
    • News / Events
      • Press Releases
      • IR Calendar
      • Email Alerts
    • Company Information
      • Profile
      • Leadership Team
      • Contacts
      • FAQ
    • Financial Information
      • Balance Sheet
      • Income Statement
      • Cash Flow
      • Financial Results
    • Stock Data
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • All SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Corporate Governance
      • Board of Directors
      • Governance Documents
  • Contact
News & Media

News & Media

  • Overview
  • Press Releases
  • BioSig in the News
  • Events

Press Releases

ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19

July 8, 2020

BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors

July 1, 2020

BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering

June 29, 2020

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

June 24, 2020

ViralClear Partners with Catalent on Potential Treatment for COVID-19

June 22, 2020

ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19

June 17, 2020

Reminder - BioSig Subsidiary, ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials of its Broad-Spectrum Oral Anti-Viral Candidate for Treatment of COVID-19

June 8, 2020

ViralClear adds St. David's HealthCare in Austin, Texas, to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19

June 5, 2020

BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions

June 4, 2020

BioSig Technologies Expands Intellectual Property Portfolio

June 3, 2020
  • Previous
    • 1...
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • 21
    • ...36
    Next
    Award
    BioSig Technologies, Inc.
    Sign Up for BioSig Updates Contact Us
    x formerly known as twitter icon X formerly known as Twitter
    linkedin Facebook
    © 2025 BioSig Technologies, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap